Myopia Management: From Efficacy to Integrated Evidence

More than 80 publications investigating Essilor Stellest lenses† or highly aspherical lenslets (HAL) spectacle lenses have contributed to the evidence base supporting myopia management with spectacle lenses. A recently released clinical summary infographic, developed in collaboration with Myopia Profile’s Dr Kate Gifford, highlighted seven key evidence areas underpinning Essilor Stellest lenses, including the potential for Essilor Stellest lenses to slow myopia progression, delay myopia onset, maintain visual performance while controlling myopia progression, and attain additional benefit when used in conjunction with atropine. The infographic is reproduced by accessing the link below.

The Foundation: Efficacy and Long-Term Outcomes

The foundation of the evidence supporting HAL spectacle lenses was established through a two-year randomised controlled clinical trial involving 157 myopic children in Wenzhou, China. Compared with single-vision lenses, children wearing HAL spectacle lenses experienced significantly slower myopia progression and axial elongation, establishing the efficacy of this spectacle lens approach for myopia management.¹

Importantly, continued follow-up of children enrolled in the randomised clinical trial has provided valuable insight into the long-term performance of HAL spectacle lenses. Five-year findings demonstrated sustained treatment benefits,² while seven-year follow-up data presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 meeting provided further evidence of long-term efficacy. The analysis included 40 participants who completed seven years of follow-up, representing approximately 71% retention from the original treatment group. Investigators reported cumulative slowing of myopia progression by 2.30D and axial elongation by 0.92 mm compared with extrapolated control group outcomes and this was observed in participants up to 19 years of age (Figure 1, above).³

More recently, findings from a prospective, randomised, double-masked, multicentre clinical trial, conducted across nine clinical sites in the United States, further expanded this body of evidence. Presented at ARVO 2026, the trial demonstrated slowing of myopia progression by 71% (0.64D) and axial elongation by 53% (0.24 mm) over two years compared with single-vision lenses.⁴

Efficacy was observed across age groups and baseline myopia levels, with stronger effects reported among younger children.⁵ Investigators also reported stable visual acuity, favourable safety outcomes, and high treatment compliance.⁶ Additional analyses indicated no impact on the rate of astigmatism change over two years compared to single vision lenses,⁷ confirming previously reported results in Chinese paediatric populations.^8,9

Essilor Stellest lenses received United States Food and Drug Administration (US FDA) market authorisation in September 2025¹⁰ and are currently the first and only spectacle lenses authorised in the US.

Presented at ARVO 2026, the trial demonstrated slowing of myopia progression by 71% (0.64D) and axial elongation by 53% (0.24 mm) over two years compared with single-vision lenses

Bringing Clinical Trials and Real-World Practice Together

Beyond individual clinical trials, clinicians increasingly rely on evidence generated across multiple study designs, including randomised controlled trials, long-term follow-up investigations, independent research, and real-world clinical practice.

A review of published evidence across 26 studies conducted in multiple patient populations, including 17 in China, showed consistent findings for HAL spectacle lenses.^†11 Among the 10 studies that included a single vision lens control group, axial elongation in children wearing HAL spectacle lenses was consistently lower than in those wearing single vision lenses, regardless of study design or geographic location.¹¹

Real-world evidence presented at ARVO 2026 and subsequently published in Ophthalmology Science (Figure 2) reported reductions in myopia progression in clinical practice, with HAL spectacle lenses incorporating highly aspherical lenslet target (HALT)* technology associated with the greatest reduction in axial length among the spectacle lens designs evaluated.^12,13

Together, these findings highlight the robust body of evidence supporting HAL spectacle lenses across both controlled clinical studies and routine clinical practice.

Figure 2. ARVO 2026 poster evaluating published evidence across 26 studies on HAL spectacle lenses, prepared by Professor Mark Bullimore (USA) and Olga Prenat (EssilorLuxottica).

Earlier Intervention: Pre-Myopia Management

Research investigating plano HAL spectacle lenses has demonstrated reductions in axial elongation among children identified as being at risk of developing myopia compared with single vision lenses.^14-16 These findings suggest that optical interventions may have a role before the onset of myopia.

A large school-based study in Shanghai, presented at ARVO 2026, demonstrated that integrated interventions, including HAL lens wear and increased outdoor time, may help reduce incident myopia and slow axial elongation in myopic and pre-myopic children.¹⁷ Notably, among children wearing HAL spectacle lenses for at least 12 hours per day, axial elongation was reduced by 90% in pre-myopic children and 75% in myopic children compared with the control group.¹⁷

Delaying myopia onset may be particularly important, as modelling studies suggest that delaying onset by just one year could provide benefits equivalent to 2–3 years of myopia management intervention after onset.¹⁸

Personalising Care Through Combination Approaches

Combination therapy has emerged as an area of increasing interest in myopia management, particularly for children who continue to progress despite monotherapy.

Several studies have evaluated HAL spectacle lenses in combination with low-dose atropine, with findings suggesting additional benefits compared with atropine monotherapy in selected patients.^19-22

An independent study reported that combining HAL spectacle lenses with low-dose atropine (0.01–0.025%), in children who continued to progress despite atropine monotherapy, provided greater myopia progression control over 24 months compared with atropine alone.²³

These findings suggest that combining optical and pharmacological interventions may provide an additional management option for selected children at risk of continued myopia progression.

Diverse Patient Populations

Researchers are increasingly investigating outcomes in patient populations traditionally underrepresented in myopia management studies.

Emerging evidence has demonstrated favourable outcomes in children with anisometropia, intermittent exotropia, and myopia of prematurity, including slowing of myopia progression and preservation of binocular visual function.^24-26 These findings have been encouraging and suggest that evidence-based myopia management may have a role across a broader range of clinical scenarios.

Preserving Visual Performance

Studies evaluating HAL spectacle lenses have consistently shown that distance and near visual acuity, accommodation, stereoacuity, and binocular vision remain comparable to single-vision lens wear.^25,27,28 Children have also demonstrated fast adaptation to wearing HAL spectacle lenses, with all children adapting within one week of lens wear.²⁸

Importantly, there is currently no evidence of rebound in myopia progression following cessation of treatment with HAL spectacle lenses.²⁹ Analyses have shown that after the first and second year, the eye growth of 90% of children wearing HAL spectacle lenses full time was similar or slower than non-myopic children.³⁰

Together, these findings support long-term wear of HAL spectacle lenses for myopia management.

Clinical Evidence

Essilor Stellest 2.0 lenses (Figure 3) are powered by HALT Max technology, which incorporates aspherical lenslets with increased mean power and asphericity compared with Essilor Stellest lenses.³¹

Figure 3. Essilor Stellest 2.0 lenses with HALT Max technology.

Clinical evidence supporting HALT Max technology was generated through a 12-month prospective, randomised, double-masked contralateral crossover clinical trial involving 50 myopic children in Singapore.³¹ By allowing each participant to wear Essilor Stellest 2.0 lenses in one eye and Essilor Stellest lenses in the fellow eye, investigators were able to directly compare the two lens designs under identical real-world conditions.

The study found that eye growth was 1.88 times slower in eyes wearing Essilor Stellest 2.0 lenses compared with eyes wearing Essilor Stellest lenses.^§31 A dose-response relationship was observed, with increased lenslet power and asphericity associated with greater slowing of axial elongation.³¹

These findings provide clinical evidence supporting HALT Max technology and demonstrate how refinements in spectacle lens design continue to be evaluated through clinical research.³¹

Conclusion

The evidence supporting myopia management now extends beyond efficacy alone, encompassing long-term follow-up, real-world evidence, emerging patient populations, and refinements in lens technologies. Together, these findings provide clinicians with insight into how interventions perform across different patient populations, clinical settings and stages of care, supporting evidence-based decisions for children at risk of myopia.

As research continues to evolve, evidence generated from randomised clinical trials, long-term follow-up investigations, and routine clinical practice will continue to expand understanding of myopia management and support improved outcomes for children and adolescents.

This article was sponsored by EssilorLuxottica.

Sephora Miao is an optometrist and the Head of Medical and Professional Affairs for EssilorLuxottica ANZ. A graduate of UNSW with a Bachelor of Optometry (Honours), Ms Miao has contributed across industry committees, including Early Career Optometrists NSW/ACT and university advisory boards. Her research interests include myopia and posterior ocular pathology. With extensive experience across the eye care industry, Ms Miao is committed to elevating patient care standards and driving innovation in eye care across ANZ.

Notes 

This communication is intended for scientific exchange only and does not constitute medical or therapeutic recommendations.

*HALT is an acronym for highly aspherical lenslet target and does not imply a “halt” or “stop” of myopia progression.

† Essilor Stellest lens regulatory status and product availability may vary by country. Data presented may be derived from one or more clinical studies. US FDA authorisation and indications for use are based solely on clinical trial data from the US

§ Based on 12-month results from a prospective, randomised, double-masked contralateral crossover clinical trial conducted in Singapore on 50 myopic children.31 The estimated cumulative 12-month axial length change (eye growth) was 0.228 mm with Essilor Stellest lenses and 0.121 mm with Essilor Stellest 2.0 lenses. The 1.88× ratio reflects the relative difference between these values (1 / [0.121 / 0.228] = 1.88).

References

1. Bao J, Huang Y, Chen H, et al. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA Ophthalmol. 2022 May;140(5):472-8. doi: 10.1001/jamaophthalmol.2022.0401.
2. Li X, Huang Y, Bao J, et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye Vis (Lond). 2025 Mar 5;12(1):10. doi: 10.1186/s40662-025-00427-3.
3. LI X, Huang Y, Bao J, et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 7-year follow-up study. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 0968.
4. Shen J, Young G, Drobe B, et al. Two year safety and effectiveness of Stellest lenses for slowing myopia progression in a US pediatric population. ARVO 2026; 2026 May 3 7; Denver, CO. Poster 1229-0999
5. Lim EW, Shen J, Drobe B, et al. Impact of age and baseline myopia on the effectiveness of Stellest lenses in a US pediatric population. ARVO 2026 Annual Meeting; 2026 May 3 7; Denver, CO. Poster 1196-0966
6. Gelb C, Shen J, Drobe B, et al. Safety and visual acuity outcomes of Stellest lenses: 2-year results from a US pivotal trial. ARVO 2026 Annual Meeting; 2026 May 3 7; Denver, CO. Poster 1201-0971
7. Wong YL, Shen J, Drobe B, et al. Comparison of 24-month astigmatism changes between Stellest and single vision lenses in US children. ARVO 2026 Annual Meeting; 2026 May 3 7; Denver, CO. Poster 1229-0967
8. Bao J, et al. Two-year changes in cylinder power in myopic children wearing spectacle lenses with highly aspherical lenslets and single vision spectacle lenses. Invest Ophthalmol. Vis Sci. 2024 Jun 17;65(7):160-.9.
9. Wen K, Yang B, Cho P, et al. Effect of three types of specially-designed myopia control spectacle lenses on astigmatism: a two-year result. Ophthalmic Physiol Opt. 2026 Apr 8:1-7. doi: 10.1007/s44402-026-00077-5.
10. US FDA. FDA authorizes marketing of first eyeglass lenses to slow progression of pediatric myopia (media release). Sep 2025. Available at: fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia [accessed June 2026].
11. Bullimore M, Prenat O. Myopia control with spectacle lenses with highly aspherical lenslets (HAL). ARVO 2026 Annual Meeting; 2026 May 3 7; Denver, CO. Poster 0978.
12. Ganesh SC, Armentano M, Narendran K, et al. Comparative effectiveness of myopia-control spectacle lenses: Real-world performance from a retrospective cohort study. Ophthalmology Science. 2026 Feb 2:101103. doi: 10.1016/j.xops.2026.101103.
13. Liu C, Li M, Li, L, et al. Real-world effectiveness of three myopia-control spectacle lens designs in children with low myopia. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1223-0993.
14. Zhang Z, Zeng L, Chen Z, et al. Spectacle lenses with highly aspherical lenslets for slowing axial elongation and refractive change in low-hyperopic Chinese children: a randomized controlled trial. Am J Ophthalmol. 2025 Jan; 269:60-68. doi: 10.1016/j.ajo.2024.08.020.
15. Wang L, Wong YL, Drobe B, Wang X. Effectiveness of spectacle lenses with highly aspherical lenslets in slowing axial elongation among non-myopic children. Clin Exp Optom. 2026 Jul;109(5):844-850. doi: 10.1080/08164622.2025.2502527.
16. Sun A, Li X, Wu Y, et al. Real-world efficacy of plano lenses with highly aspherical lenslets in children with pre-myopia: A prospective cohort study. Ophthalmic Physiol Opt. 2025 Sep;45(6):1468-1474. doi: 10.1111/opo.13535.
17. He J, Wang J, Xu X, et al. The school-based myopia prevention and control integrated study in Shanghai: 6-month results. ARVO 2026 Annual Meeting; 2026 May 3 7; Denver, CO. Presentation 1879.
18. Bullimore MA, Brennan NA. Myopia: An ounce of prevention is worth a pound of cure. Ophthalmic Physiol Opt. 2023 Jan;43(1):116-121. doi: 10.1111/opo.13058.
19. Vagge A, Frattolillo A, Traveso CE, et al. Highly aspherical lenslet target (HALT) technology in combination with low-dose atropine to control myopia progression. Invest Ophthalmol Vis Sci 2024; 65: 2739-2739.
20. Sim Xiangrong B, Kai Lyn L, Myint Htoon H, et al. Additive effect of highly aspherical lenslet target (halt) spectacles to children inadequately controlled by atropine monotherapy. Ophthalmol Sci. 2025 Feb 26;5(4):100753. doi: 10.1016/j.xops.2025.100753.
21. Hu G, Xu Z, Deng H, et al. Therapeutic efficacy of highly aspherical lenslets combined with low-concentration atropine: a retrospective study. Photodiagnosis Photodyn Ther. 2025; 55:104779. doi: 10.1016/j.pdpdt.2025.104779.
22. Chen M, Lei H, Mao X, et al. Comparative efficacy of optical correction methods combined with 0.01% atropine in myopia control. BMC Ophthalmol. 2025;25(1):703. doi: 10.1186/s12886-025-04523-9.
23. Xiangrong BS, Lin PCH, Chia AWL, et al. Efficacy of combined highly aspherical lenslet target (HALT) spectacles and low-dose atropine in children with poor response to atropine monotherapy over 24 months. ARVO 2026 Annual Meeting; 2026 May 3 7; Denver, CO. Poster 1002.
24. Zhai J, Fang W, Lu F, et al. Effects of orthokeratology and spectacle lenses with highly aspherical lenslets on unilateral myopic anisometropia control. Ophthalmic Physiol Opt. 2024 Nov;44(7):1407-1413. doi: 10.1111/opo.13388.
25. Fengchao Z, Xue L, Jinhua B, et al. Effect of spectacle lenses with highly aspherical lenslets on binocular vision and accommodation in myopic children with and without intermittent exotropia. J Ophthalmol. 2022 Oct 12;2022:9306848. doi: 10.1155/2022/9306848.
26. Parrozzani R, Molin C, Midena E, et al. Myopia of prematurity: reduced progression using highly aspherical lenslet target (HALT) technology. J Clin Med. 2026 Jan 8;15(2):484. doi: 10.3390/jcm15020484.
27. Huang Y, Li X, Bao J, et al. Visual acuity, near phoria and accommodation in myopic children using spectacle lenses with aspherical lenslets: results from a randomized clinical trial. Eye Vis (Lond). 2022 Sep 1;9(1):33. doi: 10.1186/s40662-022-00304-3.
28. Bao J, Yang A, Chen H, et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-1176. doi: 10.1136/bjophthalmol-2020-318367.
29. Sankaridurg P, Weng R, Naduvilath T, et al. Spectacle lenses with highly aspherical lenslets for slowing myopia: a randomized, double-blind, cross-over clinical trial: Parts of these data were presented as a poster at the Annual Research in Vision and Ophthalmology meeting, 2022. Am J Ophthalmol. 2023 Mar;247:18-24. doi: 10.1016/j.ajo.2022.10.021.
30. Wong YL, Li X, Chen H, et al. Eye growth pattern of myopic children wearing spectacle lenses with aspherical lenslets compared with non-myopic children. Ophthalmic Physiol Opt. 2024 Jan;44(1):206-213. doi: 10.1111/opo.13232.
31. Nallour Raveendran R, Ong WS, Drobe B, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9. doi: 10.1167/tvst.14.11.9.